The Institute for Clinical and Economic Review (ICER) last week held a public meeting on its assessments of Duchenne muscular dystrophy treatments.
According to a STAT report, patient advocates in attendance voiced their frustrations as ICER reviewed evidence and discussed whether the price tags were justifiable.
“It’s an extremely uncomfortable position,” patient advocate Mindy Leffler, whose child has Duchenne, said during the meeting. “How am I supposed to make some comment on the value of my son’s life?”
To read the full report on STAT, click here.